Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Common Equity (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Common Equity for 8 consecutive years, with $1.5 billion as the latest value for Q1 2026.

  • For Q1 2026, Common Equity rose 95.82% year-over-year to $1.5 billion; the TTM value through Mar 2026 reached $1.5 billion, up 95.82%, while the annual FY2025 figure was $1.6 billion, 89.04% up from the prior year.
  • Common Equity hit $1.5 billion in Q1 2026 for Kymera Therapeutics, down from $1.6 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.6 billion in Q4 2025 and bottomed at $395.0 million in Q4 2023.
  • Average Common Equity over 5 years is $733.3 million, with a median of $684.9 million recorded in 2024.
  • Year-over-year, Common Equity decreased 22.88% in 2023 and then skyrocketed 125.75% in 2024.
  • Kymera Therapeutics' Common Equity stood at $490.2 million in 2022, then dropped by 19.42% to $395.0 million in 2023, then surged by 111.56% to $835.6 million in 2024, then skyrocketed by 89.04% to $1.6 billion in 2025, then dropped by 2.53% to $1.5 billion in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $1.5 billion, $1.6 billion, and $946.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.